Tuesday, August 7, 2012

Astellas Pharma: Application for Orally Disintegrating Tablet YM060, a Treatment for Diarrhea-predominant Irritable Bowel Syndrome, in Japan

Astellas Pharma Inc. today announced that it submitted an application for market authorization for “orally disintegrating tablet YM060 (generic name: ramosetron hydrochloride)” to the Ministry of Health, Labour and Welfare in Japan. It has submitted for approval for an additional formulation of Irribow with the indication of the diarrhea-predominant irritable bowel syndrome in male.

Orally disintegrating tablet YM060 has been developed using WOWTAB  which is one of the Astellas' proprietary drug delivery technologies. It can be ingested without water since it quickly disintegrates upon contact with saliva in the mouth. It can be easily taken even by elderly patients and patients with impaired swallowing function. It is also useful for patients with avoided water consumption and meets various needs of patients. Astellas offers Gaster ®D for the treatment for peptic ulcers and gastritis, Harnal ®D for the treatment for functional symptoms of benign prostatic hyperplasia and Vesicare ®OD 3) for overactive bladder, which were developed with using WOWTAB technology.